<b>Conclusion:</b> The use of PD-1/PD-L1 inhibitors increased the incidence risk of immune-related colitis and hepatitis, but this potential to increase the incidence risk of the disease was weaker than Ipilimumab. The gene discussed is CD274; the disease is hepatitis A virus infection.